These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 9815891)
1. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Pak AS; Wright MA; Matthews JP; Collins SL; Petruzzelli GJ; Young MR Clin Cancer Res; 1995 Jan; 1(1):95-103. PubMed ID: 9815891 [TBL] [Abstract][Full Text] [Related]
2. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. Young MR; Wright MA; Pandit R J Immunol; 1997 Jul; 159(2):990-6. PubMed ID: 9218621 [TBL] [Abstract][Full Text] [Related]
3. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Young MR; Wright MA; Lozano Y; Prechel MM; Benefield J; Leonetti JP; Collins SL; Petruzzelli GJ Int J Cancer; 1997 Feb; 74(1):69-74. PubMed ID: 9036872 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178 [TBL] [Abstract][Full Text] [Related]
5. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253 [TBL] [Abstract][Full Text] [Related]
6. Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells. Lathers DM; Achille N; Kolesiak K; Hulett K; Sparano A; Petruzzelli GJ; Young MR Otolaryngol Head Neck Surg; 2001 Sep; 125(3):205-12. PubMed ID: 11555755 [TBL] [Abstract][Full Text] [Related]
7. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells]. Meng FY; Xu B; Sun J; Yang Y; Niu JN Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861 [TBL] [Abstract][Full Text] [Related]
8. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317 [TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer. Day KV; Li D; Liu S; Guo M; O'Malley BW Laryngoscope; 2001 May; 111(5):801-6. PubMed ID: 11368071 [TBL] [Abstract][Full Text] [Related]
10. Treatment of human bone marrow with recombinant placenta immunoregulator ferritin results in myelopoiesis and T-cell suppression through modulation of the cytokine-chemokine networks. Moroz C; Grunspan A; Zahalka MA; Traub L; Kodman Y; Yaniv I Exp Hematol; 2006 Feb; 34(2):159-66. PubMed ID: 16459184 [TBL] [Abstract][Full Text] [Related]
11. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D Clin Cancer Res; 1999 Oct; 5(10):2735-41. PubMed ID: 10537336 [TBL] [Abstract][Full Text] [Related]
12. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Young MR; Wright MA; Lozano Y; Matthews JP; Benefield J; Prechel MM Int J Cancer; 1996 Jul; 67(3):333-8. PubMed ID: 8707405 [TBL] [Abstract][Full Text] [Related]
14. Genetically engineered tumor cell vaccine in a head and neck cancer model. Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339 [TBL] [Abstract][Full Text] [Related]